NEXGEL Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Adam Levy

Algemeen directeur

US$442.1k

Totale compensatie

Percentage CEO-salaris	73.5%
Dienstverband CEO	5.2yrs
Eigendom CEO	4.4%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.7yrs

Recente managementupdates

Recent updates

NexGel: Old Wine In A New Bottle

Jan 30

Analyse CEO-vergoeding

Hoe is Adam Levy's beloning veranderd ten opzichte van NEXGEL's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$4m
Jun 30 2024	n/a	n/a	-US$3m
Mar 31 2024	n/a	n/a	-US$3m
Dec 31 2023	US$442k	US$325k	-US$3m
Sep 30 2023	n/a	n/a	-US$3m
Jun 30 2023	n/a	n/a	-US$3m
Mar 31 2023	n/a	n/a	-US$4m
Dec 31 2022	US$450k	US$300k	-US$5m
Sep 30 2022	n/a	n/a	-US$6m
Jun 30 2022	n/a	n/a	-US$6m
Mar 31 2022	n/a	n/a	-US$5m
Dec 31 2021	US$306k	US$180k	-US$4m
Sep 30 2021	n/a	n/a	-US$3m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$2m
Dec 31 2020	US$226k	US$143k	-US$2m
Sep 30 2020	n/a	n/a	-US$2m
Jun 30 2020	n/a	n/a	-US$1m
Mar 31 2020	n/a	n/a	-US$2m
Dec 31 2019	US$129k	US$40k	-US$2m

Compensatie versus markt: De totale vergoeding ($USD 442.10K ) Adam } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van Adam is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Adam Levy (61 yo)

5.2yrs

Tenure

US$442,100

Compensatie

Mr. Adam R. Levy has been Chief Executive Officer and President of NEXGEL, Inc. since September 10, 2019 and had been its Chief Financial Officer since December 31, 2019 until June 1, 2021. He serves as Di...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Adam Levy	CEO, President & Director	3.2yrs	US$442.10k	4.43% $ 1.1m
Jerome Zeldis	Independent Director & Chairman of Scientific Advisory Board	4.6yrs	US$30.75k	1.42% $ 354.1k
Nachum Stein	Independent Director	5.2yrs	US$30.75k	6.27% $ 1.6m
Scott Henry	Independent Director	1.8yrs	US$30.75k	1.96% $ 489.9k
Stephen Brigido	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Steven Glassman	Independent Chairman	3.7yrs	US$30.75k	2.05% $ 511.8k
Stephen Banco	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Neil Chesen	Member of Scientific Advisory Board	2.2yrs	geen gegevens	geen gegevens
Leonard Nelson	Member of Scientific Advisory Board	2.2yrs	geen gegevens	geen gegevens
Kip Crecca	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens

2.7yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NXGL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.7 jaar), wat duidt op een nieuw bestuur.

NEXGEL Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

NEXGEL, Inc. Appoints Kip Crecca to Its Scientific Advisory Board

NEXGEL, Inc., Annual General Meeting, Jun 17, 2024

NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024

NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors

NEXGEL, Inc. Announces Directorate and Committee Changes

Nexgel Appoints Scott Henry, to Board of Directors and Audit Committee

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 14% to US$6.00

Forecast breakeven date moved forward to 2025

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. to Report Q3, 2024 Results on Nov 14, 2024

NEXGEL, Inc. Appoints Kip Crecca to Its Scientific Advisory Board

NEXGEL, Inc. Reiterates Revenue Guidance for the Third Quarter and Fourth Quarter of 2024

NEXGEL, Inc. has filed a Follow-on Equity Offering in the amount of $1.11 million.

NEXGEL, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Share price stability

NEXGEL, Inc. and Innovative Optics US Initiate Institutional Review Board Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal

NEXGEL, Inc. Provides Preliminary Revenue Guidance for the Second, Third and Fourth Quarter of 2024

Price target decreased by 14% to US$6.00

NEXGEL, Inc. to Report Q1, 2024 Results on May 13, 2024

NEXGEL, Inc., Annual General Meeting, Jun 17, 2024

NEXGEL, Inc. announced delayed annual 10-K filing

Forecast breakeven date pushed back to 2026

NEXGEL, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024

NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

NEXGEL, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target increased by 20% to US$6.00

New major risk - Market cap size

New major risk - Market cap size

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

NEXGEL, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Consensus revenue estimates increase by 62%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NEXGEL, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

NEXGEL, Inc. Announces Directorate and Committee Changes

Nexgel Appoints Scott Henry, to Board of Directors and Audit Committee

Forecast to breakeven in 2025

NEXGEL, Inc. Launches Turfguard to Treat Painful Turf Burns and Protect Sports-Related Wounds

NEXGEL, Inc. (NasdaqCM:NXGL) announces an Equity Buyback for $0.5 million worth of its shares.

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

NEXGEL, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NEXGEL, Inc. Reports Positive Results from Proof-Of-Concept Study for Its Diclofenac Hydrogel Pain Treatment

Nexgel, Inc. Develops New Hydrogel Patch to Treat Amblyopia

NEXGEL, Inc. Announces SAGE Journals Publishes New Data Revealing SilverSeal Hydrogel Dressing Improves Postsurgical Scarring

NEXGEL, Inc. Announces Scientific Advisory Board Appointments

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NEXGEL, Inc. to Report Q2, 2022 Results on Aug 10, 2022

NEXGEL Launches Medagel Hydroliner Pro Pads for Eyelash Protection During Cosmetic Extensions Service

NEXGEL, Inc., Annual General Meeting, Aug 30, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

NEXGEL, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

NexGel: Old Wine In A New Bottle

NEXGEL, Inc. Announces the Launch of MEDAGEL ClearComfort Hydrogel Patch

NEXGEL, Inc. has completed an IPO in the amount of $14.235131 million.

High number of new and inexperienced directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd